ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,925, issued on March 24, was assigned to LANOVA MEDICINES Ltd. (Shanghai).
"Bispecific antibodies targeting PD1 and VEGF" was invented by Runsheng Li (Shanghai), Wei Cao (Shanghai), Haijuan Gu (Shanghai), Wentao Huang (Shanghai) and Ying Qin Zang (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are bispecific antibodies capable of binding to human VEGF protein and human PD-1 protein. These bispecific antibodies are effective in treating cancer."
The patent was filed on Sept. 26, 2024, under Application No. 18/897,951.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-P...